Clinical Research Directory
Browse clinical research sites, groups, and studies.
Polygenic Risk Driven Pragmatic Statin Trial for Heart Disease Prevention
Sponsor: Mikk JÜRISSON
Summary
This research investigates the potential advantages of intensive preventive statin treatment for healthy men aged 45-80 and women aged 55-80 who possess a high genetic predisposition to coronary artery disease (CAD). By specifically targeting the top 20% of individuals with elevated CAD polygenic risk scores (PRS), the study seeks to find out whether this tailored approach can notably decrease the occurrence of cardiovascular disease and mortality over a five-year period when compared with usual care. Despite the potential of PRS in pinpointing individuals at heightened risk for cardiovascular disease, there is a lack of focused and prospective investigations in existing research. This study aims to bridge this gap by examining whether preventive statin therapy for individuals with high CAD PRS is not only effective in diminishing cardiovascular events but also economically viable. The comparison between the statin treatment arm and standard care practice is conducted in a pragmatic manner at the primary care level.
Official title: The Pragmatic EE-PRS Trial Assessing Polygenic Risk Driven Statin Therapy for Cardiovascular Disease Prevention
Key Details
Gender
All
Age Range
45 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
2500
Start Date
2025-04
Completion Date
2033-02
Last Updated
2025-03-25
Healthy Volunteers
No
Conditions
Interventions
Rosuvastatin 20mg
Preventive statin treatment with rosuvastatin 20mg, 1 tablet per day, for healthy individuals with top 20% CAD PRS.
Locations (2)
North Estonia Medical Centre
Tallinn, Harju, Estonia
Tartu University Hospital
Tartu, Tartu, Estonia